ReviewNature chemical biology2026
Unfreezing structural biology for drug discovery.
Review in Nature chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Perspectives for pharmaceutical screening at XFEL sources using the example of Lassa virus endonuclease.Acta crystallographica. Section D, Structural biology · 2026Article
- Temperature and intrinsic CaNature structural & molecular biology · 2026Article
- Biophysical Sensing Tools in Drug Discovery: Integrating Kinetics, Thermodynamics, Cellular Target Engagement and Structure.Sensors (Basel, Switzerland) · 2026Review
- Reaching the full potential of cryo-EM reconstructions with molecular dynamics simulations at 310 K: Actin filaments as an example.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Structure-based drug discovery relies on three-dimensional protein structures to provide the atomic blueprints for small-molecule design, indicating where to place each atom to maximize favorable interactions. The advent of cryo-cooling crystals in crystallography greatly accelerated the ease and accessibility of structural data, making it a mainstay of most drug discovery efforts. However, despite its successes, including producing numerous clinically successful molecules, cryo-cooled samples only tell part of the structural story: they may leave out dynamic details or introduce artifacts that may lead drug discovery campaigns astray. In this Perspective, we highlight recent studies characterizing temperature-sensitive structural phenomena observed by crystallography. We showcase how leveraging information on rare, hidden conformational states informs ligand discovery via molecular docking. This demonstrates the value of performing structural studies at elevated temperatures, closer to where biology occurs, to 'unfreeze' structural ensembles for drug discovery and design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.